신경퇴행성 질환 바이오마커 시장 - 전략적 인사이트와 예측(2026-2035년)

The Neurodegenerative Biomarkers Market is anticipated to grow at a CAGR of 11.4% from USD 4.81 billion in 2026 to USD 12.68 billion in 2035.

The neurodegenerative biomarkers market is undergoing significant transformation driven by the paradigm shift toward early disease detection and the emergence of disease-modifying therapies. The market's evolution is characterized by the growing recognition that objective biological indicators are essential for identifying neurodegenerative diseases before significant neurological decline occurs, enabling timely therapeutic intervention. The convergence of advanced analytical platforms, including immunoassays, molecular diagnostics, and neuroimaging technologies, is enabling more sensitive, specific, and accessible biomarker detection. Healthcare systems are seeking objective methods for identifying diseases such as Alzheimer's, Parkinson's, and ALS at earlier stages, as treatment effectiveness increasingly depends on intervention during preclinical or early symptomatic phases. The emergence of disease-modifying therapies continues influencing biomarker demand because treatment success relies on biological confirmation of disease status and patient stratification. Regulatory agencies increasingly recognize biomarkers as essential tools for neurological drug development, as biological evidence improves trial design and treatment evaluation. The market is witnessing significant investment in blood-based biomarker technologies, multi-omics approaches, and AI-enabled interpretation platforms, positioning neurodegenerative biomarkers as a critical component of precision neurology across global healthcare systems.

Market Drivers

• The increasing demand for early disease detection represents the primary driver for the neurodegenerative biomarkers market. Early disease detection improves opportunities for therapeutic intervention and long-term disease management. Demand for neurodegenerative biomarkers is increasing because clinicians seek methods capable of identifying pathology before significant neurological decline occurs. This requirement creates pressure on diagnostic developers to improve biomarker sensitivity and accessibility. Companies are expanding blood-based and molecular diagnostic technologies to support earlier diagnosis. The outcome is stronger adoption of biomarker-driven diagnostic strategies, resulting in sustained growth in neurodegenerative biomarker utilization. The expansion of disease-modifying therapies is further accelerating market growth through demand for patient identification and treatment monitoring. Disease-modifying therapies depend on accurate patient identification and treatment monitoring. Demand for validated biomarkers is rising because therapeutic effectiveness increasingly relies on biological confirmation of disease status. This dependency limits the usefulness of symptom-based diagnostic approaches for patient selection. Pharmaceutical developers are integrating biomarkers throughout clinical development programs to improve treatment evaluation. The result is greater utilization of biomarkers across therapeutic decision-making processes. Advancements in blood-based biomarker technologies are expanding accessibility and scalability. Blood-based testing provides a more accessible alternative to invasive diagnostic procedures. Demand for blood-derived biomarkers is increasing because healthcare providers seek scalable solutions that support broader patient access. This shift challenges traditional reliance on cerebrospinal fluid testing and advanced imaging modalities. Diagnostic companies are improving assay performance and validation standards to enhance clinical confidence. The outcome is growing adoption of blood-based biomarker testing. Increasing utilization in clinical trials is driving expansion of biomarker integration throughout neurological drug development. Clinical trial success increasingly depends on accurate identification of disease biology and progression. Demand for neurodegenerative biomarkers is rising because sponsors require objective measures capable of supporting patient selection and endpoint evaluation.

Market Restraints

• Clinical validation remains complex because neurodegenerative diseases often progress over extended periods and require long-term outcome assessment. The slow progression of these diseases creates challenges for demonstrating biomarker utility. Standardization challenges persist because biomarker testing methodologies vary across laboratories and analytical platforms. The lack of harmonized protocols reduces comparability and clinical confidence. Reimbursement uncertainty limits adoption because healthcare systems continue evaluating the clinical and economic value of emerging biomarker technologies. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of integrated diagnostic platforms and multi-omics approaches. Demand for immunoassays and molecular diagnostics is increasing because healthcare providers seek reliable and clinically accessible testing methods. This requirement exposes limitations associated with highly specialized diagnostic approaches that remain difficult to scale. NGS is expanding for genomic and transcriptomic biomarker discovery. Mass spectrometry is gaining adoption for comprehensive proteomic profiling. Neuroimaging technologies continue supporting structural and functional brain assessment. The segment analysis reveals that demand is shifting toward protein biomarkers because pathological proteins such as amyloid beta, phosphorylated tau, and neurofilament light chain increasingly support earlier disease identification. Genetic biomarkers provide insight into hereditary risk and disease susceptibility. Imaging biomarkers enable visualization of structural and functional brain changes. Metabolic and inflammatory biomarkers offer additional biological context. Alzheimer's disease represents the largest application because therapeutic innovation increasingly depends on biological confirmation of disease status. Parkinson's disease, ALS, Huntington's disease, and multiple system atrophy represent significant and growing application areas. Blood represents the fastest-growing sample type because healthcare providers seek less invasive diagnostic solutions. Cerebrospinal fluid remains important for specific applications where higher sensitivity is required. Pharmaceutical and biotechnology companies represent the leading end-user segment, with diagnostic laboratories and academic research institutes expanding biomarker utilization. The integration of AI is becoming increasingly important because biomarker research generates large and complex datasets. Industry participants are incorporating machine learning technologies to improve diagnostic accuracy and predictive performance.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and pharmaceutical companies alongside specialized biomarker, neurology, and analytical technology providers. Roche maintains a strategically distinct position because it combines pharmaceutical expertise with one of the most comprehensive diagnostics portfolios in the healthcare industry, expanding biomarker solutions designed to support diagnosis, patient stratification, and treatment monitoring within neurology care pathways. Fujirebio occupies a leading position because the company has established extensive expertise in neurodegenerative biomarker development, particularly within Alzheimer's disease diagnostics, expanding assay development and validation efforts to improve clinical implementation and accessibility. Quanterix differentiates itself through ultra-sensitive biomarker detection technologies capable of identifying low-abundance biological signals, expanding applications for its Simoa platform across Alzheimer's disease, Parkinson's disease, ALS, and related neurological disorders. Bio-Rad maintains strategic relevance because neurodegenerative biomarker development increasingly depends on advanced molecular analysis and quantitative measurement technologies, expanding molecular diagnostics and life science research capabilities to support biomarker discovery and validation initiatives. Thermo Fisher Scientific occupies an important position because the company provides a broad range of technologies supporting biomarker discovery, validation, and commercialization, expanding analytical technologies and laboratory solutions to address evolving requirements. QIAGEN maintains competitive strength through expertise in molecular diagnostics, sample preparation technologies, and biomarker development support, expanding technologies that support biomarker discovery, translational research, and clinical implementation activities. Siemens Healthineers differentiates itself through expertise in diagnostic imaging and laboratory diagnostics, both of which play important roles in neurodegenerative disease management. Companies are pursuing product portfolio expansion through innovation in blood-based biomarker assays, multi-omics platforms, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for biomarker discovery and validation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where aging populations are increasing the burden of neurodegenerative diseases.

Short Conclusion

• The neurodegenerative biomarkers market is positioned for sustained growth driven by the convergence of early disease detection, disease-modifying therapies, and technological innovation. The transition from research-focused tools toward foundational components of neurological healthcare represents a fundamental shift in disease management. While challenges related to clinical validation, standardization, and reimbursement persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with neurodegenerative biomarkers evolving into a critical component of precision neurology, supporting early diagnosis, treatment selection, therapeutic monitoring, and drug development across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Neurodegenerative Biomarkers Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Neurodegenerative Disease Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Unmet Clinical Needs Analysis
• 3.8 Epidemiology and Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Biomarker Testing Volume Analysis
• 3.11 Neurodegenerative Disease Diagnostic Pathway Analysis
• 3.12 Biomarker Role in Early Disease Detection
• 3.13 Biomarker Role in Therapeutic Monitoring

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape
• 5.4 Stakeholder Ecosystem Analysis
• 5.5 Clinical Laboratory and Diagnostic Infrastructure Analysis

6. Innovation Landscape

• 6.1 Emerging Technologies in Neurodegenerative Biomarkers
• 6.2 Product Innovation Trends
• 6.3 Clinical Trial Analysis
• 6.4 Neurodegenerative Biomarker Pipeline Analysis
• 6.5 Blood-Based Biomarker Development Trends
• 6.6 Multi-omics Biomarker Innovation
• 6.7 AI Integration in Biomarker Discovery and Interpretation
• 6.8 Digital Biomarker Development Trends
• 6.9 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements
• 7.4 Biomarker Qualification Programs
• 7.5 Diagnostic Validation Requirements

8. Neurodegenerative Biomarkers Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology Platform
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Disease Indication
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Testing Methodology
• 8.7 Analysis by End User
• 8.8 Analysis by Development Stage

9. Neurodegenerative Biomarkers Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Protein Biomarkers
  • 9.1.2 Genetic Biomarkers
  • 9.1.3 Imaging Biomarkers
  • 9.1.4 Metabolic Biomarkers
  • 9.1.5 Inflammatory Biomarkers
• 9.2 By Disease Indication
  • 9.2.1 Alzheimer's Disease
  • 9.2.2 Parkinson's Disease
  • 9.2.3 Amyotrophic Lateral Sclerosis (ALS)
  • 9.2.4 Huntington's Disease
  • 9.2.5 Multiple System Atrophy
  • 9.2.6 Other Neurodegenerative Disorders
• 9.3 By Technology Platform
  • 9.3.1 Immunoassays
  • 9.3.2 Molecular Diagnostics
  • 9.3.3 Next-Generation Sequencing (NGS)
  • 9.3.4 Mass Spectrometry
  • 9.3.5 Neuroimaging Technologies
• 9.4 By Sample Type
  • 9.4.1 Blood
  • 9.4.2 Cerebrospinal Fluid (CSF)
  • 9.4.3 Tissue Samples
  • 9.4.4 Other Biological Samples
• 9.5 By End User
  • 9.5.1 Hospitals and Clinics
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Academic and Research Institutes
  • 9.5.4 Pharmaceutical and Biotechnology Companies
  • 9.5.5 Contract Research Organizations (CROs)

10. Neurodegenerative Biomarkers Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Neurodegenerative Biomarkers Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Sweden
• 11.7 Japan
• 11.8 China
• 11.9 South Korea
• 11.10 Australia
• 11.11 India
• 11.12 Spain

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches
• 12.5 Competitive Benchmarking
• 12.6 Biomarker Development Partnership Analysis

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Fujirebio Holdings, Inc.
• 13.3 Quanterix Corporation
• 13.4 Bio-Rad Laboratories, Inc.
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 QIAGEN N.V.
• 13.7 Danaher Corporation
• 13.8 Siemens Healthineers AG
• 13.9 Revvity, Inc.
• 13.10 C2N Diagnostics, LLC
• 13.11 Eisai Co., Ltd.
• 13.12 Biogen Inc.
• 13.13 Agilent Technologies, Inc.
• 13.14 Alamar Biosciences, Inc.
• 13.15 Sysmex Corporation

14. Neurodegenerative Biomarkers Market Commercial Forecast Analysis

• 14.1 Alzheimer's Disease Biomarkers
• 14.2 Parkinson's Disease Biomarkers
• 14.3 Blood-Based Biomarker Tests
• 14.4 Cerebrospinal Fluid Biomarker Tests
• 14.5 Imaging Biomarker Solutions
• 14.6 Neurofilament Light Chain (NfL) Biomarker Solutions
• 14.7 Amyloid and Tau Biomarker Solutions

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments
• 15.4 Neuroscience Research Funding Landscape
• 15.5 Precision Neurology Investment Trends
• 15.6 Biomarker Development Funding Analysis

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends
• 16.3 Evolution of Blood-Based Neurodegenerative Biomarkers
• 16.4 AI-Driven Biomarker Discovery Outlook
• 16.5 Future of Early Disease Detection and Monitoring
• 16.6 Long-Term Market Outlook (2035)